Trump’s Psychedelics Order: What’s Still Missing |
Psychedelics may induce powerful temporary states, but lasting change is not guaranteed.
The therapeutic effect of psychedelic-assisted therapy (PAP) appears tied to the subjective experience.
Without structured integration, insights gained during PAP may fade or fail to stabilize.
Meditation may help convert transient psychedelic effects into lasting psychological traits.
On April 18, 2026, Donald Trump signed an executive order to accelerate the development of psychedelic drugs as medical treatments. It directs the Food and Drug Administration (FDA) to fast-track compounds already designated as “breakthrough therapies,” encourages interagency data sharing, and outlines a pathway for rapid rescheduling if approved. It also commits $50 million in federal funding.
If implemented as intended, psychedelic-assisted psychotherapy (PAP) could move into broader clinical use within a few years. This urgency reflects the persistence of treatment-resistant depression, PTSD, and addiction—including among veterans—and the limited effectiveness of existing treatments.
This raises two essential questions. First, is PAP safe and effective enough for FDA approval? Second, if it is, how should it be practiced to produce durable outcomes?
The first question is being actively studied. The second remains underdeveloped, yet may prove just as important.
How Psychedelics Appear to Work
A growing body of research suggests PAP offers a novel approach to difficult-to-treat conditions. Unlike conventional medications, psychedelics appear to work by inducing specific subjective experiences.
These “mystical-type” experiences involve a temporary dissolution of self-boundaries, a sense of unity, and altered perceptions of time and space. Their intensity strongly predicts therapeutic outcomes. While some argue the effect is primarily pharmacological, the prevailing view is that the subjective experience drives the change.
At the neural level, psychedelics reduce activity in the brain’s default mode network (DMN), associated with self-referential thinking, and increase neuroplasticity, promoting new neural connections. In this sense, they function as biological catalysts, temporarily increasing the brain’s capacity to reorganize itself.
However, this neuroplastic window is brief. The brain becomes more impressionable, but without structure, it may revert to prior patterns. The opportunity for change is real, but not self-sustaining.
The State-to-Trait Problem
Psychedelics reliably induce powerful psychological states—temporary shifts in perception and identity. For lasting benefit, these states must translate into traits: enduring patterns of thought, behavior, and emotional regulation.
This “state-to-trait” conversion is not guaranteed. A profound experience may feel transformative, yet leave underlying patterns largely unchanged.
This clarifies a central limitation of current PAP models: They induce beneficial states, but do not consistently stabilize them into lasting traits.
A Parallel Mechanism in Meditation
Meditation offers a useful comparison. Like psychedelics, it reduces DMN activity and can produce experiences of self-transcendence. But its effects emerge through repetition.
Rather than inducing a single state, meditation trains the capacity to access and sustain similar modes of awareness. Over time, this repeated exposure reshapes baseline patterns of attention and reactivity.
From this perspective, psychedelics and meditation may operate along a shared continuum. Psychedelics provide rapid access to a state of openness. Meditation develops the capacity to maintain and integrate that openness.
The Limits of a Session-Based Model
Current PAP protocols typically involve one to three high-dose sessions, supported by preparation and integration, and have produced striking short-term results.
Yet the conditions being treated are chronic, reflecting patterns formed over years. If the mechanism depends on a temporary state, a limited number of sessions may not produce lasting change.
The question is not whether PAP can initiate transformation, but whether that transformation can be sustained.
Integration is widely recognized as essential, but remains loosely defined and variable. It often consists of intermittent therapy sessions without a standardized method for maintaining the flexibility induced during the psychedelic experience.
This creates a risk of insight without lasting change. Patients may gain clarity yet struggle to translate it into stable behavioral shifts.
Meditation offers a more structured approach. It provides a repeatable method for revisiting and stabilizing the same modes of awareness, supporting consolidation over time.
There is also a question of timing. Emerging research suggests that the days immediately following a psychedelic session may represent a period of heightened neuroplasticity—sometimes referred to as an “afterglow”—during which the brain is especially receptive to new patterns of thought and behavior. Integration may therefore be most effective when it begins within this window. A structured meditation practice introduced during this period could help guide the consolidation of new patterns, increasing the likelihood that transient insight becomes lasting change.
Implications for Research Design
The current policy shift creates an opportunity to address this gap. As new trials are designed, they will shape not only whether PAP is approved, but how it is practiced.
If PAP is evaluated in isolation, a key variable may be missed. Including structured contemplative practices would allow critical questions to be tested: whether meditation sustains benefits, reduces relapse, enhances integration, or decreases the need for repeated dosing.
More specifically, trials could include a “Contemplative-Informed Integration” arm. This would incorporate standardized daily protocols, such as Mindfulness-Based Cognitive Therapy (MBCT) or other established meditation practices, including automatic self-transcending approaches such as Transcendental Meditation, designed to help translate the insights of the psychedelic experience into ongoing practice.
Without such comparisons, conclusions about long-term effectiveness will remain incomplete.
Beyond Symptom Reduction
Most psychiatric research focuses on symptom reduction. These outcomes are essential. Yet both psychedelic and meditation research suggest broader effects, including increased well-being, meaning, and prosocial behavior.
If treatment is defined narrowly, a limited number of psychedelic sessions may suffice. If the goal is sustained psychological health, however, a one-time intervention is unlikely to be enough. It must be followed by a process that supports continued change.
Meditation offers such a process. It is accessible, scalable, and does not depend on repeated pharmacological intervention.
Toward a More Complete Model
Taken together, psychedelics appear to induce a temporary but transformative state that increases neuroplasticity and enables psychological reorganization, while meditation provides a practical means of stabilizing and extending these changes over time.
This model is both testable and clinically relevant. It aligns with current neuroscience, subjective reports, and the chronic nature of the conditions being treated.
The executive order accelerating psychedelic research marks a significant shift in mental health policy. It reflects a willingness to explore treatments that engage subjective experience as well as neurobiology.
But if the goal is to determine not only whether PAP works, but how it can be made optimally effective, something remains missing. That missing piece is not another compound or dosing strategy, but a recognition that the mechanism of healing may need to extend beyond the session itself.
Future research should reflect this. Including meditation as a core variable in study design would not complicate the science; it would clarify it. Without a stabilizing practice, we may offer patients a glimpse of transformation without a reliable way to sustain it. Integrating meditation into psychedelic research moves the field toward a more durable model of psychological health.
Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344.
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197.
Brewer, J. A., Worhunsky, P. D., Gray, J. R., Tang, Y.-Y., Weber, J., & Kober, H. (2011). Meditation experience is associated with differences in default mode network activity and connectivity. Proceedings of the National Academy of Sciences, 108(50), 20254–20259.
There was a problem adding your email address. Please try again.
By submitting your information you agree to the Psychology Today Terms & Conditions and Privacy Policy